What does this research mean for the field?

Obicetrapib demonstrates a favorable 12-month safety profile comparable to placebo, with similar overall adverse event rates (60.2% vs 62.0%) and discontinuations (4.1% vs 5.3%) in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This analysis aims to comprehensively evaluate the safety profile of obicetrapib in later-stage clinical trials.

March 26, 2026Open Access

Obicetrapib safety analysis: pooled phase 3 clinical trial experience

Key Result

Obicetrapib demonstrated a favorable 12-month safety profile comparable to placebo, with similar overall adverse event rates (60.2% vs 62.0%) and discontinuations (4.1% vs 5.3%).

Key Points

This analysis aims to comprehensively evaluate the safety profile of obicetrapib in later-stage clinical trials.
Pooled analysis of two phase III trials
Participants received obicetrapib 10 mg daily or placebo for 365 days
Safety outcomes included treatment-emergent adverse events and prespecified events of special interest.
Overall treatment-emergent adverse event rates were similar between obicetrapib and placebo (60.2% vs 62.0%)
AEs leading to treatment discontinuation were lower in the obicetrapib group (4.1% vs 5.3%)
Reduction in eGFR occurred less often with obicetrapib (0.9% vs 2.0%)
No significant differences in blood pressure or severe adverse events between groups.

Structured PICO

Does obicetrapib 10 mg daily affect the rate of treatment-emergent adverse events compared to placebo in adults with HeFH or ASCVD?

Population

2,880 adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD), mean age 64 years, 36% female, 82% with ASCVD, 35% with diabetes.

Intervention

Obicetrapib 10 mg daily for 365 days

Comparator

Placebo

Outcome

Treatment-emergent adverse events (TEAEs) and prespecified events of special interest including hepatic, muscular, glycemic, renal and ocular parameters as well as overall rates of discontinuation over 365 dayssafety

Obicetrapib 10 mg daily demonstrated a favorable safety profile over 12 months, with adverse event rates comparable to placebo in patients with HeFH or ASCVD.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

Obicetrapib is a potent, selective cholesteryl ester transfer protein (CETP) inhibitor that lowers LDL-C and raises HDL-C. Although prior studies have demonstrated efficacy and general tolerability, a comprehensive evaluation of its safety profile across later-stage clinical trials is needed. Safety outcomes were assessed in a pooled analysis of two phase III trials comparing obicetrapib 10 mg daily with placebo in adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD). Participants received treatment for 365 days. Safety endpoints included treatment-emergent adverse events (TEAEs) and prespecified events of special interest including hepatic, muscular, glycemic, renal and ocular parameters as well as overall rates of discontinuation. A total of 2,880 participants were included (mean age 64 years; 36% female; 82% with ASCVD; 35% with diabetes). Overall TEAE rates were similar between obicetrapib and placebo (60.2% vs 62.0%). AEs leading to treatment discontinuation occurred in 4.1% of obicetrapib-treated participants and 5.3% on placebo, Risk Ratio (RR) 0.77 0.54-1.08. No clinically significant change in blood pressure was observed between groups and hypertension events were comparable. There was no difference between the groups in liver or muscle-related endpoints. Reduction in eGFR occurred less often with obicetrapib (0.9 vs. 2.0%, RR 0.25, 0.90). Macular degeneration was reported once in the obicetrapib group (n=1, 0.1%). Deaths were similar between treatment groups. No new safety signals were identified. Obicetrapib demonstrated a favorable safety profile over 12 months, with AE rates comparable to placebo. These findings extend our understanding of the safety and tolerability of obicetrapib.